Fig. 5
From: A high-throughput screening assay to identify inhibitory antibodies targeting alphavirus release
Dose responses for varying dilutions of human polyclonal sera. Samples from three volunteers with previous exposure to CHIKV (TT018, TT002, and TT024) at different times post symptom onset (4, 195, and 240 dpo respectively) were screened using the anti-budding assay system. All volunteers were previously (TT002 and TT024) or at enrollment (TT018) confirmed by RT-PCR. Serum from one volunteer with an ongoing ZIKV infection (5 dpo) and no evidence of any exposure to CHIKV was included as a specificity control (TT101). Different serum dilutions were tested to determine an appropriate dilution range for the anti-budding assay. Positive control mAb C9 (2 mg/mL) was included for comparison. Nano-luciferase readings from control wells containing no antibody were set at 100%. Results were calculated as a percentage of these control wells and represent the mean ± S.D of triplicate measurements. All results shown carry a CV score of ≤ 15%